News and Analysis

Small molecules against RNA targets attract big backers

Novartis, Merck, Pfizer and biotech entrepreneurs have started working on small-molecule drugs that act on an assortment of RNA targets, hoping to unlock once undruggable targets and new biology.

  • Subscribe to Nature Reviews Drug Discovery for full access:

    $265

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

Authors

  1. Search for Asher Mullard in: